| DIA | SEMANA | MÊS | 3 MESES | 6 MESES | 12 MESES | NO ANO |
|---|---|---|---|---|---|---|
| +3,53% | +13,80% | +11,89% | +18,39% | −0,14% | −28,74% | +1,66% |
| DIA | SEMANA | MÊS | 3 MESES | 6 MESES | 12 MESES | NO ANO | |
|---|---|---|---|---|---|---|---|
| BIOM3 | +3,53% | +13,80% | +11,89% | +18,39% | −0,14% | −28,74% | +1,66% |
| IBOV | +1,38% | +8,82% | +12,63% | +17,54% | +5,95% | +47,53% | +29,75% |
| CDI | 0,00% | +0,20% | +1,08% | +3,31% | +6,78% | +14,38% | +10,84% |
Biomm S.A. operates as a biotechnology company in Brazil. The company offers insulin products for the treatment of diabetes, including AFREZZA, a human insulin powder for inhalation; GLARGILIN, a glargine insulin; WOSULIN N and WOSULIN R; Lifepen G, a reusable insulin injection pen; and Biopemm, a reusable insulin delivery device for diabetic patients. It also provides Bevyx for the treatment of metastatic colorectal…